Skip to content

An explorative study to assess the changes in disease status in patients with systemic amyloidosis using amyloid PET/CT

An explorative study to assess the changes in disease status in patients with systemic amyloidosis using amyloid PET/CT

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0007077
Enrollment
75
Registered
2022-03-11
Start date
2022-01-19
Completion date
Unknown
Last updated
2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

The Catholic University of Korea, Seoul St. Mary's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) 19 years of age or older 2) In case of histological diagnosis of amyloidosis 3) If you voluntarily agree to participate in the study

Exclusion criteria

Exclusion criteria: 1) In case of uncontrolled severe disease other than multiple myeloma 2) Decompensated heart failure inability to lie down immediately for 1 hour 3) Severe claustrophobia that does not improve even with the use of sedatives 4) Pregnant or lactating women 5) Serious liver disease 6) History of epilepsy

Design outcomes

Primary

MeasureTime frame
In patients with amyloidosis, dynamic changes in the degree of amyloid deposition are checked using amyloid PET/CT images before and after treatment.

Secondary

MeasureTime frame
To evaluate the cardiac function of patients with amyloidosis and the degree of cardiac involvement on amyloid PET/CT.;Diagnosis of organ involvement in amyloid PET/CT in patients with amyloidosis, and evaluation of correlation with hematologic disease markers and other imaging test results.;To evaluate the association of amyloid PET/CT with haematological and affected organ responses after treatment of amyloidosis patients. To evaluate the potential of amyloid PET/CT as a therapeutic response evaluation tool.;To evaluate the potential of amyloid PET/CT as a predictive tool for post-treatment response and survival in patients with amyloidosis.;To evaluate the possibility of amyloid PET/CT as a tool to predict multiple myeloma-associated amyloidosis in patients with multiple myeloma.;To compare and evaluate the cognitive function test results of patients with amyloidosis and the degree of brain amyloid deposition on amyloid PET/CT.

Countries

Korea, Republic of

Contacts

Public ContactJung Yeon Lee

The Catholic University of Korea, Seoul St. Mary's Hospital

jungyeon1029@naver.com+82-2-2258-6049

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026